INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinoma (UTUC) is an uncommon malignancy, accounting for only five percent of urothelial cancers. Traditionally, nephroureterectomy (NU) with removal of an ipsilateral bladder cuff has been the standard for treatment of this disease entity. However, less invasive, kidneysparing techniques are becoming more widely embraced. The use of ureteroscopy for the management of UTUC has been advocated in select circumstances such as in patients with a solitary kidney or bilateral disease. Based on our multiple decade experience with this technique, however, we champion a more robust role for this technique and present here our patient experience and outcomes with the use of endoscopy in the management of UTUC.
METHODS: An extensive retrospective review was performed of over two hundred patients with UTUC initially managed by a single endourologic surgeon. Patients were seen over a 21 year period from 1994-2015 with initial evaluations occurring from 1994-2008.Evaluations were performed on patient and tumor characteristics as well as surgical parameters. Statistical analyses were utilized to determine factors affecting patient outcomes.
RESULTS: A total of 258 patients diagnosed with UTUC were initially evaluated and managed by a single surgeon. 1486 procedures were performed with mean of 7.0 procedures per patient over the period of evaluation. Average tumor size on initial ureteroscopic excision was 16.8 mm (range 1-60) while average recurrent tumor size was 6.4 mm (range 1-50). Of this patient cohort, 94.2% were white and 66% were male. Patients with low grade tumors were successfully managed longterm, with 70.6% of patients avoiding NU. Even in cases of patients with high tumor volume, ureteroscopic management was associated with relatively long-term patient survival. Seventy patients ultimately underwent NU for reasons including conversion to high grade, tumor burden, patient choice and difficult endoscopic access. Multivariate analysis revealed no association of tumor location with survival. Patients with at least a 5 year follow up had overall survival 46.3% and recurrence free survival (RFS) 22%. In this subpopulation, patients with initial grade 1 tumors had RFS of 37.8%. Their average follow up was 7.1 years (range 5-20).
CONCLUSIONS: We have demonstrated that ureteroscopic management of UTUC is a successful alternative to NU for patients with low grade tumors. This work presents a comprehensive investigation of tumor characteristics as well as patient outcomes over a twenty one year period of management of patients with UTUC by a single initial surgeon. METHODS: 42 out of 50 (84%) UTUC patients managed conservatively were included in prospective analysis from January 2011 to October 2016. Inclusion criteria were high-risk UTUC diagnosis (one or more high-risk EAU guidelines features), meanwhile exclusion criteria were pT1 or grade III biopsy in elective cases, invasive tumour aspect on CT-urography or previous radical cystectomy. ET was performed both retrograde and anterograde access with rigid and digital flexible ureteroscope or percutaneous access. Endoscopic ablation was performed with Ho: YAG laser. The variables analysed were: age, sex, history of bladder cancer, elective/imperative indication, hydronephrosis, urine cytology, tumour grade and stage, tumour size (¼1cm/>1cm), tumour location and multifocality. Statistical analysis was performed using Chi square test or categorical variables. Overall Survival (OS) and Cancer Specific Survival (CSS) were calculated using Kaplan-Meier analysis. A p value <0.05 was considered to indicate statistical significance. SPSS 17.0 software was used RESULTS: Elective and imperative indications occurred in 20 (47,6%) and 22 (52,4%) cases, respectively. Median age was 65 years (46-83) and 35 (70%) were male. Hydronephrosis on diagnosis was present in 17 (40,5%) and high-grade cytology in 4 cases (9,8%). Multifocality were in 21 (50%) and tumour size was >1cm in 23 (54,8%). Biopsies showed grade I in 23 (54,8%) and grade II in 17 (40,5%). Tumour stage was pTa in 37 (88%). ET was possible in 33 out of 42 (78,6%), where 17 (85%) were elective and 16 (72,7%) were imperative. Renal preservation was possible in 18 (94,7%) ¼1cm tumours and in 15 (62,2%) >1cm, being tumour size the only predictive variable of renal preservation. At 20 months (1-69) of follow up, recurrence was noted in 26 cases (61,9%) and grade progression in 6 (14,31%). The median OS was 51,8 months (42-61) and the median CSS was 56,7 months (47-65) with significant difference between imperative and elective cases. No death occurred in elective cases. Renal preservation survival (time until nephroureterectomy) was 42 months (33-51).
Source of
CONCLUSIONS: According to our results, conservative endoscopic treatment should play a more important role in selected high-risk UTUC patients. It suggests a revision of the EAU guidelines recommendations . Peri-operative cisplatin-based therapy (CBT) is a standard of care for muscle invasive bladder UC, but requires adequate renal function which may be a limiting factor after definitive surgery for UUT carcinoma. In this study, we evaluate the outcomes of patients with UUT-SPTs after radical cystectomy (RC), with an emphasis on change in renal function associated with extirpative surgical treatment and eligibility for perioperative CBT.
METHODS: From January 1996 to October 2016, two surgeons at a high volume academic institution performed 486 consecutive RCs for bladder UC. Excluding patients with prior UUT carcinoma, 26 patients developed UUT-SPTs requiring surgical treatment and were the focus of this study. Patient outcomes were measured using end points of survivorship and estimated glomerular filtration rate (eGFR) in relation to tumor stage, tumor grade and time from RC to SPT.
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